User contributions
Jump to navigation
Jump to search
- 21:06, 25 September 2022 diff hist 0 m Penile cancer current
- 21:04, 25 September 2022 diff hist -9 m Soft tissue sarcoma current
- 21:03, 25 September 2022 diff hist 0 m Prostate cancer current
- 21:02, 25 September 2022 diff hist 0 m Pancreatic cancer current
- 21:02, 25 September 2022 diff hist -132 m Ovarian cancer current
- 21:00, 25 September 2022 diff hist 0 m Osteosarcoma current
- 20:53, 25 September 2022 diff hist +33 m Glioblastoma current
- 20:43, 25 September 2022 diff hist 0 m Gastric cancer - null regimens current
- 20:42, 25 September 2022 diff hist 0 m Esophageal cancer current
- 20:40, 25 September 2022 diff hist 0 m Esophageal adenocarcinoma current
- 20:38, 25 September 2022 diff hist +4 m Cervical cancer current
- 20:36, 25 September 2022 diff hist 0 m Breast cancer, HER2-positive current
- 20:23, 25 September 2022 diff hist 0 m Breast cancer current
- 20:20, 25 September 2022 diff hist +27 m Bladder cancer current
- 20:19, 25 September 2022 diff hist -42 m Bladder cancer
- 20:17, 25 September 2022 diff hist -1 m Venous thromboembolism current
- 20:16, 25 September 2022 diff hist -20 m T-cell acute lymphoblastic leukemia, pediatric current
- 20:14, 25 September 2022 diff hist -8 m T-cell acute lymphoblastic leukemia →Subsequent treatment current
- 14:41, 25 September 2022 diff hist +666 m Non-small cell lung cancer current
- 14:30, 25 September 2022 diff hist +224 m Non-small cell lung cancer - null regimens current
- 14:27, 25 September 2022 diff hist +2 m Non-Hodgkin lymphoma, pediatric current
- 14:27, 25 September 2022 diff hist -12 m Non-Hodgkin lymphoma, pediatric
- 14:25, 25 September 2022 diff hist +169 m Neuroblastoma current
- 14:23, 25 September 2022 diff hist +72 m Low-grade glioma, pediatric current
- 14:22, 25 September 2022 diff hist +39 m Head and neck cancer current
- 14:15, 25 September 2022 diff hist +45 m Head and neck cancer - null regimens →Subsequent treatment current
- 14:13, 25 September 2022 diff hist +352 m B-cell acute lymphoblastic leukemia, pediatric current
- 12:42, 25 September 2022 diff hist +514 m Ewing sarcoma current
- 12:33, 25 September 2022 diff hist +570 m Rectal cancer current
- 12:23, 25 September 2022 diff hist +49 m Regimen classes →5-FU-based chemoradiotherapy current
- 12:21, 25 September 2022 diff hist +98 m Rectal cancer - null regimens current
- 12:21, 25 September 2022 diff hist +35 m Regimen classes →Chemoradiotherapy
- 12:20, 25 September 2022 diff hist +288 m Breast cancer - historical current
- 12:18, 25 September 2022 diff hist +133 m Multiple myeloma, relapsed-refractory current
- 12:14, 25 September 2022 diff hist -499 m Multiple myeloma, consolidation and maintenance current
- 12:10, 25 September 2022 diff hist 0 m Multiple myeloma current
- 12:02, 25 September 2022 diff hist 0 m Multiple myeloma, induction current
- 12:01, 25 September 2022 diff hist +356 m Multiple myeloma, induction
- 11:50, 25 September 2022 diff hist +31 m Low-grade glioma →Preceding treatment current
- 01:12, 25 September 2022 diff hist +626 m Breast cancer
- 00:58, 25 September 2022 diff hist +129 m Breast cancer - null regimens current
- 23:46, 24 September 2022 diff hist +124 m Small cell lung cancer current
- 23:43, 24 September 2022 diff hist +114 m Small cell lung cancer - null regimens current
- 23:41, 24 September 2022 diff hist +176 m Pancreatic cancer
- 23:37, 24 September 2022 diff hist +25 m Ovarian cancer
- 20:41, 24 September 2022 diff hist +166 m Ovarian cancer - null regimens →Preceding treatment current
- 20:39, 24 September 2022 diff hist +381 m Hodgkin lymphoma current
- 20:28, 24 September 2022 diff hist +58 m Hodgkin lymphoma - null regimens →Preceding treatment current
- 12:06, 24 September 2022 diff hist +660 m Diffuse large B-cell lymphoma
- 11:59, 24 September 2022 diff hist +28 m Regimen classes →Rituximab-containing regimen